Skip to main content



) --




) hit a new 52-week high Friday as it is currently trading at $18.63, above its previous 52-week high of $18.19 with 274,775 shares traded as of 9:41 a.m. ET. Average volume has been 815,800 shares over the past 30 days.

Alkermes has a market cap of $1.7 billion and is part of the

health care

sector and


industry. Shares are up 47.6% year to date as of the close of trading on Thursday.

Alkermes, Inc., an integrated biotechnology company, provides extended-release injectable and oral products for the treatment of prevalent and chronic diseases, such as central nervous system disorders, reward disorders, addiction, diabetes, and autoimmune disorders.

  • Practice your ALKS trading strategies and win cash in our stock game.

TheStreet Ratings rates Alkermes as a


. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full

Alkermes Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center